Comparative analysis of radiomics and deep-learning algorithms for survival prediction in hepatocellular carcinoma.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
05 Jan 2024
05 Jan 2024
Historique:
received:
16
07
2023
accepted:
20
12
2023
medline:
6
1
2024
pubmed:
6
1
2024
entrez:
5
1
2024
Statut:
epublish
Résumé
To examine the comparative robustness of computed tomography (CT)-based conventional radiomics and deep-learning convolutional neural networks (CNN) to predict overall survival (OS) in HCC patients. Retrospectively, 114 HCC patients with pretherapeutic CT of the liver were randomized into a development (n = 85) and a validation (n = 29) cohort, including patients of all tumor stages and several applied therapies. In addition to clinical parameters, image annotations of the liver parenchyma and of tumor findings on CT were available. Cox-regression based on radiomics features and CNN models were established and combined with clinical parameters to predict OS. Model performance was assessed using the concordance index (C-index). Log-rank tests were used to test model-based patient stratification into high/low-risk groups. The clinical Cox-regression model achieved the best validation performance for OS (C-index [95% confidence interval (CI)] 0.74 [0.57-0.86]) with a significant difference between the risk groups (p = 0.03). In image analysis, the CNN models (lowest C-index [CI] 0.63 [0.39-0.83]; highest C-index [CI] 0.71 [0.49-0.88]) were superior to the corresponding radiomics models (lowest C-index [CI] 0.51 [0.30-0.73]; highest C-index [CI] 0.66 [0.48-0.79]). A significant risk stratification was not possible (p > 0.05). Under clinical conditions, CNN-algorithms demonstrate superior prognostic potential to predict OS in HCC patients compared to conventional radiomics approaches and could therefore provide important information in the clinical setting, especially when clinical data is limited.
Identifiants
pubmed: 38182664
doi: 10.1038/s41598-023-50451-3
pii: 10.1038/s41598-023-50451-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
590Informations de copyright
© 2024. The Author(s).
Références
Altekruse, S. F., Devesa, S. S., Dickie, L. A., McGlynn, K. A. & Kleiner, D. E. Histological classification of liver and intrahepatic bile duct cancers in SEER registries. J. Regist. Manag. 38, 201–205 (2011).
Jemal, A. et al. Annual report to the nation on the status of cancer, 1975–2014 featuring survival. J. Natl. Cancer Inst. 109, djx030 (2017).
pubmed: 28376154
pmcid: 5409140
doi: 10.1093/jnci/djx030
Reig, M. et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J. Hepatol. 76, 681–693 (2022).
pubmed: 34801630
doi: 10.1016/j.jhep.2021.11.018
Vitale, A. et al. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona clinic liver cancer stages: A multicentre study. J. Hepatol. 62, 617–624 (2015).
pubmed: 25450706
doi: 10.1016/j.jhep.2014.10.037
Huitzil-Melendez, F.-D. et al. Advanced hepatocellular carcinoma: Which staging systems best predict prognosis?. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 28, 2889–2895 (2010).
doi: 10.1200/JCO.2009.25.9895
Wakabayashi, T. et al. Radiomics in hepatocellular carcinoma: A quantitative review. Hepatol. Int. 13, 546–559 (2019).
pubmed: 31473947
doi: 10.1007/s12072-019-09973-0
Ahn, J. C., Qureshi, T. A., Singal, A. G., Li, D. & Yang, J.-D. Deep learning in hepatocellular carcinoma: Current status and future perspectives. World J. Hepatol. 13, 2039–2051 (2021).
pubmed: 35070007
pmcid: 8727204
doi: 10.4254/wjh.v13.i12.2039
Denzler, S. et al. Impact of CT convolution kernel on robustness of radiomic features for different lung diseases and tissue types. Br. J. Radiol. 94, 20200947 (2021).
pubmed: 33544646
pmcid: 8010534
doi: 10.1259/bjr.20200947
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik und Therapie des Hepatozellulären Karzinoms und biliärer Karzinome, Langversion 4.0, 2023, AWMF-Registernummer: 032–053OL. https://www.leitlinienprogramm-onkologie.de/leitlinien/hcc-und-biliaere-karzinome .
Wiesner, R. H. et al. MELD and PELD: Application of survival models to liver allocation. Liver Transplant. Off. Publ. Am. Assoc. Study Liver Dis. Int. Liver Transplant. Soc. 7, 567–580 (2001).
Malinchoc, M. et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 31, 864–871 (2000).
pubmed: 10733541
doi: 10.1053/he.2000.5852
Johnson, P. J. et al. Assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach—The ALBI grade. J. Clin. Oncol. 33, 550–558 (2015).
pubmed: 25512453
doi: 10.1200/JCO.2014.57.9151
Pugh, R. N., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C. & Williams, R. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 60, 646–649 (1973).
pubmed: 4541913
doi: 10.1002/bjs.1800600817
Nebelung, H. et al. Radioembolization versus portal vein embolization for contralateral liver lobe hypertrophy: Effect of cirrhosis. Abdom. Radiol. 46, 4046–4055 (2021).
doi: 10.1007/s00261-021-03048-1
Fedorov, A. et al. 3D slicer as an image computing platform for the quantitative imaging network. Magn. Reson. Imaging 30, 1323–1341 (2012).
pubmed: 22770690
pmcid: 3466397
doi: 10.1016/j.mri.2012.05.001
Han, J. K. et al. Factors influencing vascular and hepatic enhancement at CT: Experimental study on injection protocol using a canine model. J. Comput. Assist. Tomogr. 24, 400 (2000).
pubmed: 10864075
doi: 10.1097/00004728-200005000-00008
Fiz, F. et al. Contrast administration impacts CT-based radiomics of colorectal liver metastases and non-tumoral liver parenchyma revealing the “radiological” tumour microenvironment. Diagnostics 11, 1162 (2021).
pubmed: 34202253
pmcid: 8305553
doi: 10.3390/diagnostics11071162
Zwanenburg, A., Leger, S., Vallières, M. & Löck, S. Image biomarker standardisation initiative. Radiology 295, 328–338 (2020).
pubmed: 32154773
doi: 10.1148/radiol.2020191145
Zwanenburg, A. et al. Assessing robustness of radiomic features by image perturbation. Sci. Rep. 9, 614 (2019).
pubmed: 30679599
pmcid: 6345842
doi: 10.1038/s41598-018-36938-4
Zwanenburg, A. & Löck, S. familiar: End-to-end automated machine learning and model evaluation (2021).
Paszke, A. et al. PyTorch: An imperative style, high-performance deep learning library. In Advances in Neural Information Processing Systems Vol. 32 (eds Paszke, A. et al.) (Curran Associates Inc, 2019).
Hosny, A. et al. Deep learning for lung cancer prognostication: A retrospective multi-cohort radiomics study. PLoS Med. 15, e1002711 (2018).
pubmed: 30500819
pmcid: 6269088
doi: 10.1371/journal.pmed.1002711
Starke, S. et al. 2D and 3D convolutional neural networks for outcome modelling of locally advanced head and neck squamous cell carcinoma. Sci. Rep. 10, 15625 (2020).
pubmed: 32973220
pmcid: 7518264
doi: 10.1038/s41598-020-70542-9
Nie, D. et al. Multi-channel 3D deep feature learning for survival time prediction of brain tumor patients using multi-modal neuroimages. Sci. Rep. 9, 1103 (2019).
pubmed: 30705340
pmcid: 6355868
doi: 10.1038/s41598-018-37387-9
Katzman, J. L. et al. DeepSurv: Personalized treatment recommender system using a Cox proportional hazards deep neural network. BMC Med. Res. Methodol. 18, 24 (2018).
pubmed: 29482517
pmcid: 5828433
doi: 10.1186/s12874-018-0482-1
Efron, B. 10 Nonparametric Confidence Intervals. In The Jackknife, the Bootstrap and Other Resampling Plans (ed. Efron, B.) 75–90 (Society for Industrial and Applied Mathematics, 1982). https://doi.org/10.1137/1.9781611970319.ch10 .
doi: 10.1137/1.9781611970319.ch10
Wei, L. et al. A deep survival interpretable radiomics model of hepatocellular carcinoma patients. Phys. Med. 82, 295–305 (2021).
pubmed: 33714190
pmcid: 8035300
doi: 10.1016/j.ejmp.2021.02.013
Liu, Q.-P., Xu, X., Zhu, F.-P., Zhang, Y.-D. & Liu, X.-S. Prediction of prognostic risk factors in hepatocellular carcinoma with transarterial chemoembolization using multi-modal multi-task deep learning. eClinicalMedicine 23, 100379 (2020).
pubmed: 32548574
pmcid: 7284069
doi: 10.1016/j.eclinm.2020.100379
Wang, H. et al. Development and validation of a deep learning model for survival prognosis of transcatheter arterial chemoembolization in patients with intermediate-stage hepatocellular carcinoma. Eur. J. Radiol. 156, 110527 (2022).
pubmed: 36152524
doi: 10.1016/j.ejrad.2022.110527
Zhang, L. et al. Deep learning predicts overall survival of patients with unresectable hepatocellular carcinoma treated by transarterial chemoembolization plus sorafenib. Front. Oncol. https://doi.org/10.3389/fonc.2020.593292 (2020).
doi: 10.3389/fonc.2020.593292
pubmed: 33928019
pmcid: 7787160
Liu, Y. et al. CT radiomics combined with clinical variables for predicting the overall survival of hepatocellular carcinoma patients after hepatectomy. Transl. Oncol. 26, 101536 (2022).
pubmed: 36115077
pmcid: 9483805
doi: 10.1016/j.tranon.2022.101536
Liu, Q. et al. A radiomics nomogram for the prediction of overall survival in patients with hepatocellular carcinoma after hepatectomy. Cancer Imaging 20, 82 (2020).
pubmed: 33198809
pmcid: 7667801
doi: 10.1186/s40644-020-00360-9
Zheng, B.-H. et al. Radiomics score: A potential prognostic imaging feature for postoperative survival of solitary HCC patients. BMC Cancer 18, 1148 (2018).
pubmed: 30463529
pmcid: 6249916
doi: 10.1186/s12885-018-5024-z
Meng, X.-P. et al. Radiomics analysis on multiphase contrast-enhanced CT: A survival prediction tool in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Front. Oncol. https://doi.org/10.3389/fonc.2020.01196 (2020).
doi: 10.3389/fonc.2020.01196
pubmed: 33680905
pmcid: 7786369
Bernatz, S. et al. CT-radiomics and clinical risk scores for response and overall survival prognostication in TACE HCC patients. Sci. Rep. 13, 533 (2023).
pubmed: 36631548
pmcid: 9834236
doi: 10.1038/s41598-023-27714-0
Mackin, D. et al. Measuring computed tomography scanner variability of radiomics features. Investig. Radiol. 50, 757–765 (2015).
doi: 10.1097/RLI.0000000000000180
Berenguer, R. et al. Radiomics of CT features may be nonreproducible and redundant: Influence of CT acquisition parameters. Radiology 288, 407–415 (2018).
pubmed: 29688159
doi: 10.1148/radiol.2018172361
Lu, L., Ehmke, R. C., Schwartz, L. H. & Zhao, B. Assessing agreement between radiomic features computed for multiple CT imaging settings. PLoS One 11, e0166550 (2016).
pubmed: 28033372
pmcid: 5199063
doi: 10.1371/journal.pone.0166550
Jin, H. & Kim, J. H. Evaluation of feature robustness against technical parameters in CT radiomics: Verification of phantom study with patient dataset. J. Signal Process. Syst. 92, 277–287 (2020).
doi: 10.1007/s11265-019-01496-z
Ziegelmayer, S. et al. Feature robustness and diagnostic capabilities of convolutional neural networks against radiomics features in computed tomography imaging. Investig. Radiol. 57, 171–177 (2022).
doi: 10.1097/RLI.0000000000000827
Huynh, B. N. et al. Head and neck cancer treatment outcome prediction: A comparison between machine learning with conventional radiomics features and deep learning radiomics. Front. Med. https://doi.org/10.3389/fmed.2023.1217037 (2023).
doi: 10.3389/fmed.2023.1217037
Whitfield, J. B. Gamma glutamyl transferase. Crit. Rev. Clin. Lab. Sci. 38, 263–355 (2001).
pubmed: 11563810
doi: 10.1080/20014091084227
Xu, X.-S. et al. Model based on γ-glutamyltransferase and alkaline phosphatase for hepatocellular carcinoma prognosis. World J. Gastroenterol. WJG 20, 10944–10952 (2014).
pubmed: 25152598
doi: 10.3748/wjg.v20.i31.10944
Yang, Z. et al. Elevation of serum GGT and LDH levels, together with higher BCLC staging are associated with poor overall survival from hepatocellular carcinoma: A retrospective analysis. Discov. Med. 19, 409–418 (2015).
pubmed: 26175398
Ma, W., Wang, H. & Teng, L. Correlation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomy. World J. Surg. Oncol. 11, 212 (2013).
pubmed: 23981851
pmcid: 3844510
doi: 10.1186/1477-7819-11-212
Tandon, P. & Garcia-Tsao, G. Prognostic indicators in hepatocellular carcinoma: A systematic review of 72 studies. Liver Int. Off. J. Int. Assoc. Study Liver 29, 502–510 (2009).
Lu, X.-Y. et al. Pathobiological features of small hepatocellular carcinoma: Correlation between tumor size and biological behavior. J. Cancer Res. Clin. Oncol. 137, 567–575 (2011).
pubmed: 20508947
doi: 10.1007/s00432-010-0909-5
Wu, G. et al. Importance of tumor size at diagnosis as a prognostic factor for hepatocellular carcinoma survival: A population-based study. Cancer Manag. Res. 10, 4401–4410 (2018).
pubmed: 30349373
pmcid: 6188157
doi: 10.2147/CMAR.S177663
Lau, T. & Ahmad, J. Clinical applications of the model for end-stage liver disease (MELD) in hepatic medicine. Hepatic Med. Evid. Res. 5, 1–10 (2013).
Hagan, M. T. et al. Liver volume in the cirrhotic patient: Does size matter?. Dig. Dis. Sci. 59, 886–891 (2014).
pubmed: 24504591
pmcid: 4565509
doi: 10.1007/s10620-014-3038-1
Kim, S. et al. Radiomics on gadoxetic acid-enhanced magnetic resonance imaging for prediction of postoperative early and late recurrence of single hepatocellular carcinoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 25, 3847–3855 (2019).
doi: 10.1158/1078-0432.CCR-18-2861
Teixeira, L. O. et al. Impact of lung segmentation on the diagnosis and explanation of COVID-19 in chest X-ray images. Sensors 21, 7116 (2021).
pubmed: 34770423
pmcid: 8587284
doi: 10.3390/s21217116